Considerations for Pneumococcal Conjugate Vaccine (PCV) Product Choice

1 September 2021
 | Publication
Considerations for Pneumococcal Conjugate Vaccine (PCV) Product Choice
Download (624.2 kB)

Overview

This document summarizes current technical and programmatic information on WHO prequalified PCV products to facilitate informed country choices for PCV introduction or product switch for childhood immunization programmes. Three PCV products are prequalified by the World Health Organization (WHO) for use in infants and children. They include the 13-valent PCV manufactured by Pfizer (PCV-13, Prev(e)nar®), a 10-valent PCV manufactured by GlaxoSmithKline (PCV-10 GSK , Synflorix®), and a 10-valent PCV manufactured by Serum Institute of India (PCV-10 SII , PNEUMOSIL®). Manufacturers are expected to seek WHO prequalification for additional higher valent PCV products in the future. This summary of considerations may be updated in the future to address new products.

WHO Team
Agenda, Policy & Strategy (APS), Immunization, Vaccines and Biologicals (IVB)
Number of pages
8
Reference numbers
ISBN: 978-92-4-003060-2 (electronic version) 978-92-4-003061-9 (print version)
Copyright